Abstract
Context: We report a novel case of insulin autoimmune syndrome (IAS) presenting with hypoglycemia due to production of a monoclonal anti-insulin antibody in a patient subsequently found to have multiple myeloma (MM). Objective: The aim of the study was to describe the 5-yr clinical course of a patient with IAS and MM and to characterize the origin and function of the pathogenic antibody. Methods: We conducted a longitudinal case history with laboratory investigations to characterize the anti-insulin antibody subtype, specificity, affinity, and origin. Results: The patient presented with IAS, which worsened during treatment of hepatitis C. The patient was then discovered to have a monoclonal gammopathy that progressed to MM. Treatment of the MM induced remission of the neoplasia and IAS, which then followed a synchronized course of progression and response to therapy. An anti-insulin IgG 3-λ that bound specifically but with low affinity to the insulin B chain (amino acids 9-30) and that was distinct from the primary MM IgG3-λ clone was recovered from the patient and cloned. The antibody bound insulin and showed mutations of normal affinity maturation. Conclusions: We describe a case of MM heralded by IAS, where full characterization of the pathogenic antibody revealed that the monoclonal anti-insulin antibody had originated from a self-reactive clone. Copyright © 2012 by The Endocrine Society.
Cite
CITATION STYLE
Waldron-Lynch, F., Inzucchi, S. E., Menard, L., Tai, N., Preston-Hurlburt, P., Hui, P., … Herold, K. C. (2012). Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma. Journal of Clinical Endocrinology and Metabolism, 97(12), 4317–4323. https://doi.org/10.1210/jc.2012-2388
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.